Therapixel

Therapixel is a French medical imaging technology company founded in 2013 by researchers Olivier Clatz and Pierre Fillard. The company specializes in artificial intelligence applied to radiology, with a strong focus on breast cancer detection. Its flagship product, MammoScreen™, is an AI-powered software that assists radiologists in interpreting digital mammograms. This software uses deep learning algorithms trained on over a million annotated mammograms to detect and characterize suspicious tissue, enhancing diagnostic accuracy and reducing missed cancer cases. MammoScreen is FDA-cleared and CE-marked, ensuring compliance with quality standards. Therapixel's technology is based on applied mathematics and computer vision, providing healthcare professionals with timely information to improve medical image interpretation. The company operates research teams in Paris and software development in Nice. It has formed partnerships, such as with RamSoft, to expand its reach in delivering AI-powered breast imaging solutions. Therapixel is also advancing research in predictive radiology, aiming to enhance breast cancer screening workflows through innovative time sequence analysis.

• Employees 58
• Founded 2013
• Annual Revenue $4500000
• Total Funding $22088205